ScoreWhy is TScan Therapeutics, Inc. ?
1
The company has declared Negative results for the last 5 consecutive quarters
- OPERATING CASH FLOW(Y) Lowest at USD -131.32 MM
2
Risky -
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of -31.83%, its profits have fallen by -27.1%
3
High Institutional Holdings at 87.48%
- These investors have better capability and resources to analyse fundamentals of companies than most retail investors.
4
Underperformed the market in the last 1 year
- Even though the market (S&P 500) has generated returns of 11.87% in the last 1 year, the stock has hugely underperformed and has generate negative returns of -31.83% returns
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to TScan Therapeutics, Inc. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is TScan Therapeutics, Inc. for you?
High Risk, Low Return
Absolute
Risk Adjusted
Volatility
TScan Therapeutics, Inc.
-18.9%
-1.00
88.41%
S&P 500
16.08%
0.62
19.30%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
-81.40%
EBIT Growth (5y)
-289.38%
EBIT to Interest (avg)
-34.67
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.02
Sales to Capital Employed (avg)
0.05
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
87.48%
ROCE (avg)
0
ROE (avg)
0
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.42
EV to EBIT
0.57
EV to EBITDA
0.58
EV to Capital Employed
76.14
EV to Sales
-10.07
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
13345.33%
ROE (Latest)
-98.26%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
Bullish
Bollinger Bands
Mildly Bearish
Mildly Bearish
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Mildly Bullish
Dow Theory
Mildly Bearish
No Trend
OBV
Mildly Bearish
No Trend
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend15What is working for the Company
NET SALES(HY)
Higher at USD 5.59 MM
NET PROFIT(HY)
Higher at USD -72.66 MM
RAW MATERIAL COST(Y)
Fallen by -6,122.73% (YoY
-3What is not working for the Company
OPERATING CASH FLOW(Y)
Lowest at USD -131.32 MM
Here's what is working for TScan Therapeutics, Inc.
Net Sales
At USD 5.59 MM has Grown at 252.49%
Year on Year (YoY)MOJO Watch
Sales trend is very positive
Net Sales (USD MM)
Net Sales
Higher at USD 5.59 MM
than preceding 12 month period ended Sep 2025MOJO Watch
In the half year the company has already crossed sales of the previous twelve months
Net Sales (USD MM)
Net Profit
Higher at USD -72.66 MM
than preceding 12 month period ended Sep 2025MOJO Watch
In the half year the company has already crossed Net Profit of the previous twelve months
Net Profit (USD MM)
Raw Material Cost
Fallen by -6,122.73% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for TScan Therapeutics, Inc.
Operating Cash Flow
Lowest at USD -131.32 MM and Fallen
In each year in the last three yearsMOJO Watch
The company's cash revenues from business operations are falling
Operating Cash Flows (USD MM)
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
